论文部分内容阅读
9月3日,北京北太平庄花园路7号,新时代大厦四层。国家知识产权局专利复审委员会这个看上去很普通很安静的地方,成为一个战场。 一场国内众多企业与跨国公司的专利之争复审裁决在此剑拔弩张:审判伟哥(英文名Viagra,正式中文名万艾可本文以下统称“伟哥”)。这场持久的审判将决定美国辉瑞制药公司生产的伟哥和其他类似药物在中国的命运,更重要的是,这案例对判断一个专利是否具备创造性突破,不少人藉此解读中国《专利法》的深处,并辨别中国对知识产权保护的风向。而2个月前的英国法院否决了辉瑞长达9年的专利申请。
September 3, Beijing North Taipingzhuang Garden Road on the 7th, New Age Building, fourth floor. The State Intellectual Property Office Patent Reexamination Board looks very ordinary and quiet place to become a battlefield. A number of domestic enterprises and multinational corporations patent dispute review verdict in this rattling: trial Viagra (English name Viagra, hereinafter referred to as the official Chinese name of Viagra, “Viagra”). This long trial will determine the fate of Viagra and other similar drugs produced by Pfizer in the United States. More importantly, this case will judge whether a patent has a creative breakthrough. Many people take this interpretation of China’s “Patent Law” Depth, and to discern China’s wind direction of intellectual property protection. Two months ago, the British court rejected Pfizer’s patent application for nine years.